Brokers Issue Forecasts for Opus Genetics FY2025 Earnings

Opus Genetics, Inc. (NASDAQ:IRD) – HC Wainwright cut their FY2025 earnings estimates for shares of Opus Genetics in a research report issued on Tuesday, April 1st. HC Wainwright analyst M. Caufield now expects that the company will post earnings per share of ($1.09) for the year, down from their previous forecast of ($1.03). HC Wainwright currently has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Opus Genetics’ current full-year earnings is ($1.22) per share. HC Wainwright also issued estimates for Opus Genetics’ FY2026 earnings at ($0.73) EPS, FY2027 earnings at ($0.52) EPS and FY2028 earnings at ($0.22) EPS.

Separately, Jones Trading cut their price objective on shares of Opus Genetics from $9.00 to $8.00 and set a “buy” rating on the stock in a research report on Tuesday.

Opus Genetics Stock Down 9.6 %

Opus Genetics stock opened at $0.89 on Thursday. Opus Genetics has a 12 month low of $0.81 and a 12 month high of $1.56. The business has a fifty day moving average of $1.06. The company has a market capitalization of $28.40 million, a P/E ratio of -0.81 and a beta of 0.28.

Opus Genetics (NASDAQ:IRD) last released its earnings results on Monday, March 31st. The company reported ($1.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.93). The business had revenue of $3.40 million for the quarter, compared to analysts’ expectations of $11.10 million. Opus Genetics had a negative net margin of 324.45% and a negative return on equity of 63.65%.

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.